Introduction
Oral mucositis (OM) is one of the most problematic complications associated with allogeneic haematopoietic SCT (allo-HSCT). OM is associated with increased mortality and morbidity, principally from infection, as well as significant pain, dysgeusia, difficulty speaking and difficulty receiving nutrition, hydration and oral medications. Severe mucositis is also associated with prolonged hospitalization, and increased costs of care. [1] [2] [3] [4] [5] [6] Although OM is caused largely by the toxicity associated with the chemoradiotherapy conditioning regimen, it is also associated with the use of MTX prophylaxis for GVHD. 7 MTX, in high doses, has an established role as an antimetabolite chemotherapeutic agent in the treatment of a range of haematological malignancies, including ALL and high-grade lymphomas. 8, 9 In lower doses, the immunosuppressive and anti-inflammatory properties of MTX provide the rationale for its use, most commonly in combination with CYA, as GVHD prophylaxis following allo-HSCT. 10, 11 Unfortunately, although MTX has been shown to be a highly effective agent for the prevention of GVHD, its use may be associated with considerable toxicity, including delayed engraftment, hepatotoxicity and, particularly, mucositis. Given the potential mortality and morbidity associated with these toxicities, and the difficulty and expense associated with the use of 5,10-methylenetetrahydrofolate reductase genotyping to predict which patients carry the TT genotype and so may be more susceptible to MTX toxicity, it has become common practice to schedule MTX prophylaxis post transplant and omit one or, rarely, two scheduled doses of MTX if unacceptable toxicity occurs or is anticipated. 12 The alternative approach to preventing mucosal toxicity due to the intracellular depletion of folates by MTX is to supplement the MTX therapy with folic/folinic acid. This approach appears logical as folic/folinic acid has been shown to reduce the toxicities of MTX when it is used in autoimmune disorders, including improved compliance with MTX therapy in patients with rheumatoid arthritis and by reducing the adverse effects associated with the use of MTX in high-intermediate dose chemotherapy protocols for various neoplastic disorders. [13] [14] [15] [16] [17] At the same time, folic/folinic acid supplementation does not appear to significantly reduce the effectiveness of MTX in rheumatoid arthritis and other autoimmune conditions, interfere with killing of leukaemia cells or increase the risk of leukaemic relapse. [13] [14] [15] [16] [17] Although folic/folinic acid might therefore be expected to improve the tolerability of MTX after HSCT, the major concern regarding its use in this setting has been the theoretical risk that it may abrogate the anti-GVHD activity of MTX. Those studies that have been conducted provide reassurance. A recent retrospective analysis of 311 patients who underwent HSCT for chronic myeloid leukaemia found that folic acid supplementation was not associated with an increased risk of GVHD or relapse post-HSCT. 18 Folic acid supplementation during MTX immunosuppression is not associated with early toxicity, risk of acute GVHD or relapse following haematopoietic transplantation. Torres et al. 19 reported 57 patients undergoing BMT who were randomly assigned to receive either CsA or MTX followed by folinic acid rescue. They found that the MTX/folinic acid group showed similar efficacy in the prevention of GVHD with the additional advantage of reduced renal and hepatic toxicities. Another study looked at the influence of post-MTX folinic acid rescue on regimenrelated toxicity and GVHD after allo-HSCT. 20 A total of 32 consecutive patients received CsA and MTX with folinic acid rescue as GVHD prophylaxis. Total 50 consecutive transplant patients given the CsA/MTX combination without folinic acid were utilized as historical controls. Folinic acid rescue showed reduced regimen-related toxicity in patients receiving CsA/MTX GVHD prophylaxis without significantly influencing the incidence of GVHD or event-free survival. Similarly, Russell et al. 21 showed that addition of folinic acid post-MTX after allogeneic transplantation could improve tolerance to the regimen without inhibiting its ability to prevent GVHD and so ensured that the full and complete scheduled MTX dose was given.
As with many other aspects of transplantation, there appears to be considerable variance between transplant centres with regards to the use of folinic acid following MTX. A 1995 survey of 87 EBMT participating centres, for example, found that 37 were using folinic acid rescue after MTX in the transplant setting. 22 In an effort to address practice variability and provide a sound evidence base for transplant practices, the EBMT Working Party for Paediatric Diseases and International BFM Study Group-Subcommittee Bone Marrow Transplantation, proposed a uniform policy for GVHD prophylaxis and therapy for their members based on the results of a large survey carried out within the European paediatric transplant centres. This policy recommended that folinic acid (15 mg/m 2 per day) should be administered 24 h after MTX to reduce the incidence and severity of adverse effects of MTX, including myelosuppression and mucosal toxicity. 23 There is no such uniform consensus policy in adult transplant groups regarding GVHD prophylaxis or for the use of folic/folinic acid following MTX.
Given the potential, albeit contested, benefits of folinic acid in the transplant setting and the limited data regarding its use in transplantation in adults, this study's aims were twofold: one to describe the usage of folinic acid in the paediatric and adult transplant centres in Australia and New Zealand and two, to elucidate the reasons why transplant centres make decisions to use, or not to use, folinic acid following the administration of MTX as prophylaxis for GVHD.
Methods
Surveys were sent by post and email to all transplant centres performing allogenic transplantation in Australia and New Zealand (n ¼ 22). Participants were asked to answer 16 questions about transplant activity in the previous 12 months ( [2004] [2005] , the incidence and severity of mucositis, grading of mucositis, use of MTX for GVHD prophylaxis, use of folinic acid in the transplant setting and the rationale for their policy regarding folinic acid use. The study was approved by the institutional ethics committee and the executive of the Australian Bone Marrow Transplant Registry (ABMTR).
Results

Respondents
units performed umbilical cord blood transplants. All units used myeloablative conditioning and 11 adult units and 1 paediatric unit also performed transplants with reducedintensity conditioning (RIC) regimens.
Mucositis and grading of oral toxicity Eleven (61%) units graded mucositis following allogeneic transplant with all but one of these units assessed mucositis on a daily basis. A number of different grading systems were used including the World Health Organization, 24 National Cancer Institute (NCI), 25 Bearman, 26 oral mucositis index (OMI) 27 and University of Nebraska 28 systems. Assessment of OM was performed by a range of staff including; transplant physicians (four), transplant registrars (four), oral physicians/dentists (three) and nursing staff (four).
MTX administration
All units used MTX for GVHD prophylaxis in myeloablative transplants whereas 11 (61%) units also used MTX as part of GVHD prophylaxis in RIC transplants. The most common regimen used for myeloablative transplants was the 'Seattle protocol', which uses 15 mg/m 2 of MTX on day þ 1 and 10 mg/m 2 on days þ 3, þ 6 and þ 11.
29
Thirteen (72%) respondents indicated that over 75% of patients were administered the complete scheduled MTX doses, whereas three (17%) units reported that 51-75% of patients received all scheduled doses and two (11%) units reported that greater than 50% received all the scheduled doses of MTX. The most common reasons given for omitting scheduled doses of MTX were mucositis (n ¼ 15, 83%) and renal dysfunction (n ¼ 1, 5%).
Folinic acid administration
Of the 18, 12 (66%) transplant units (that responded to this survey) used folinic acid following MTX for GVHD prophylaxis. Eight (44%) administered folinic acid routinely following each dose of MTX whereas four (22%) Of those units that used folinic acid, 11 (61%) did so on the grounds that it would reduce the risk/severity of mucositis, whereas 4 (33%) indicated that they did so to limit the myelotoxic effects of MTX. Of those units that did not routinely administer folinic acid following MTX (n ¼ 6), all indicated that they did so because they considered that there was no evidence of efficacy in this setting, whereas three (50%) indicated that they did not administer folinic acid because of the possibility that it may increase the risk of acute GVHD.
Discussion
Oral mucosal toxicity presents one of the most difficult challenges in transplantation as it is associated with substantial morbidity, contributes to transplant-related mortality and has been largely resistant to most of the interventions designed to reduce its incidence and severity. Although a Cochrane Systematic review of 71 studies involving 5217 patients receiving chemotherapy found a number of agents had some benefit in preventing or reducing the severity of mucositis, including amifostine, antibiotic pastes or pastilles, hydrolytic enzymes and ice chips, in all instances the benefit was modest and/or of limited clinical significance, and in some instances, the therapy was onerous or unpleasant (as with ice chips) or itself was associated with considerable toxicity (as with amifostine). 30 More promisingly, recent studies of Palifermin, a recombinant humanized keratinocyte growth factor has demonstrated that it may reduce the incidence, severity and duration of mucositis following allo-HSCT. 31, 32 Most reviews and original research has, however, addressed the problems of mucositis following chemotherapy, rather than specifically post-HSCT, and where such research has been conducted in the transplant setting, the concern (appropriately) has been with the impact of chemoradiotherapy conditioning regimens on the mucositis, rather than specifically on the potential harms associated with the post transplant administration of MTX, an agent well known to cause stomatitis and mucositis. The place of folinic acid in preventing or ameliorating MTX toxicity, particularly mucositis, has in contrast, received little attention and its use in transplant centres appears to be more a matter of medical culture and precedent than evidence-based prescribing.
This survey found that 33% of adult and 67% of paediatric of the transplant centres (that responded to the survey) in Australia and New Zealand routinely use folinic acid to reduce mucositis following post transplant MTX. The majority of centres that did not use folinic acid chose not to do so either because of the belief that there was no evidence to support its use, or, because of concerns that it may increase the likelihood of acute GVHD. We also found that not all transplant units graded mucositis and that a number of different grading systems were used.
These results are noteworthy for three reasons. First, they provide a further reminder of the differences that exist between transplant centres and even between paediatric and adult transplant units and of the need for ongoing debate about the desirability of standardizing transplant practices. Although one may postulate that paediatric transplant centres more often use folinic acid post-BMT because they have more (relative) experience with high-dose MTX-containing regimens and have always been concerned with minimizing the long-term toxicities of chemoradiotherapy and transplantation, we are unable to explain these differences on the basis of this survey. Second, this study raises questions both about the practice of using folinic acid in situations when mucositis is already established or is becoming apparent (wherein the administration of folinic acid is too late) and about decisions not to use folinic acid because it is ineffective and/or may increase the risk of acute GVHD. The effectiveness of MTX is largely attributable to its role as an inhibitor of dihydrofolate reductase and the reduction of the intercellular folate substrate pool. And while the quality of evidence in support of folinic acid following MTX in the transplant setting is weak, there are data to suggest that it may reduce MTX toxicity in the transplant (and nontransplant) setting and there is no data that support the claim that its use diminishes the effectiveness of MTX as prophylaxis for GVHD. [18] [19] [20] Finally, the finding that outside of clinical trials not all transplant units grade mucositis and, when/where they do, they use a range of different grading systems, is troubling because uniform grading is necessary for consistent assessments and for providing the basis for meaningful comparisons between patient populations, conditioning regimens and interventions to prevent or treat mucositis.
Mucositis remains a significant problem and, whereas there are now promising biological therapies in trial and in practice (most notably Palifermin) these are expensive and even if effective, do not remove the need to consider therapies that specifically counter the toxicity of MTX, particularly where mucositis may lead to some patients not receiving the full scheduled dose of post transplant MTX and therefore potentially be at greater risk of acute GVHD. Ongoing research to establish more effective and less toxic regimens for reducing GVHD is essential. At the same time, however, in the absence of adverse data regarding the use of folinic acid in the transplant setting, it is worthwhile asking again what role folinic acid can, or should, have in preventing and/or limiting the severity and duration of oral mucosal toxicity.
